CA
NZ
UK
AU
IND
US
InvenTrust Properties Corp. filed a Form 8-K on November 4, 2026, disclosing the appointment of Robert A. Garechana to its Board of Directors and Audit Committee, effective immediately.
Salvatore J. Ternullo, Chief Executive Officer and Director of SVRN, Inc., filed an amended initial statement of beneficial ownership on November 4, 2026, correcting how a restricted stock award was previously categorized and reflecting share counts adjusted for a 1-for-20 reverse stock split.
Robert Garechana submitted an initial statement of beneficial ownership as a newly appointed director of InvenTrust Properties Corp., filed on November 4, 2026, disclosing no securities beneficially owned.
Robert Wong, VP and Chief Accounting Officer of Retension Pharmaceuticals, Inc., filed an initial statement of beneficial ownership with the SEC on November 4, 2026, disclosing no securities held as of his event date of November 2, 2026.
Jonathan Rubin, SVP and Chief Medical Officer of Supernus, Inc., filed a Form 4 on November 4, 2026, disclosing changes in beneficial ownership resulting from the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., effective November 2, 2026.
Timothy C. Dec, Senior Vice President and Chief Financial Officer of Supernus, Inc., filed a Form 4 on November 4, 2026, disclosing changes to his beneficial ownership resulting from the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. that became effective on November …
SVRN, Inc. filed a Form 6-K on November 4, 2026, announcing the appointment of Patrick O'Kain as Chief Operating Officer effective November 3, 2026, following the resignation of David Schwed from that role.
Frank Mottola, SVP and Chief Technology Operations Officer of Supernus, Inc., filed a Form 4 on November 4, 2026, disclosing changes in beneficial ownership of common stock and equity awards resulting from a merger that became effective on November 2, 2026.
Jack A. Khattar, Chief Executive Officer and Director of Supernus, Inc. (NASDAQ:SUPN), filed a Form 4 on November 4, 2026, disclosing changes in his beneficial ownership of common stock and equity awards resulting from the November 2, 2026 effective date of the merger between …
Director Georges Gemayel filed a Form 4 with the SEC on November 4, 2026, disclosing changes in beneficial ownership of Supernus, Inc. (NASDAQ:SUPN) common stock and equity awards resulting from the merger effective November 2, 2026, between Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Please wait processing your request...